Example: Heart Attack

Clinical Trials on Angioimmunoblastic T-cell Lymphoma

Total 261 results

NCT03853044

Recruiting

Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma

Conditions: Angioimmunoblastic T-cell Lymphoma
NCT03273452

Unknown status

Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide)

Conditions: Angioimmunoblastic T-cell Lymphoma
NCT03593018

Recruiting

Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL

Conditions: Relapsed Angioimmunoblastic T-Cell Lymphoma; Refractory Angioimmunoblastic T-cell Lymphoma
NCT00169156

Completed

A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma

Conditions: Untreated T-cell Angioimmunoblastic Lymphoma
NCT00070291

Terminated

Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma

Conditions: Lymphoma
NCT02273739

Completed

Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation

Conditions: Solid Tumor; Glioma; Angioimmunoblastic T-cell Lymphoma; Intrahepatic Cholangiocarcinoma; Chondrosarcoma
NCT00958854

Unknown status

Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma

Conditions: Lymphoma
NCT04251065

Recruiting

A Multicenter Clinical Trial of Daratumumab in Combination With Gemcitabine, Dexamethasone and Cisplatin in Patients With Relapsed/Refractory CD38 Positive PTCL-NOS, Angioimmunoblastic T-cell Lymphoma AITL and Other Nodal Lymphomas of T Follicular Helper Cells Origin

Conditions: Refractory T-Cell Lymphoma; Relapsed T-Cell Lymphoma
NCT04319601

Recruiting

Rituximab Combined With Chidamide and Lenalidomide for r/r AITL

Conditions: Angioimmunoblastic T-cell Lymphoma; Chemotherapy Effect; Chemotherapeutic Toxicity
NCT02520791

Active, not recruiting

Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma

Conditions: Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Recurrent Angioimmunoblastic T-Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3a Follicular Lymphoma; Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent Mycosis Fungoides; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory Angioimmunoblastic T-Cell Lymphoma; Refractory Grade 1 Follicular Lymphoma; Refractory Grade 2 Follicular Lymphoma; Refractory Grade 3a Follicular Lymphoma; Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Stage IB Mycosis Fungoides AJCC v7; Stage II Mycosis Fungoides AJCC v7; Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma; Stage III Mycosis Fungoides AJCC v7; Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma; Stage IV Mycosis Fungoides AJCC v7
NCT03070964

Terminated

A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma

Conditions: Lymphoma
NCT01553786

Completed

Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)

Conditions: T-cell Lymphoma
NCT03703375

Recruiting

Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

Conditions: Lymphoma, T-Cell
NCT03040206

Completed

Risk Stratification of Nodal PTCL

Conditions: Peripheral T-Cell Lymphoma, Not Otherwise Specified; Angioimmunoblastic T-cell Lymphoma; Anaplastic Large Cell Lymphoma, ALK-negative
NCT03552692

Terminated

Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma

Conditions: T-Cell Lymphoma Relapsed; T-Cell Lymphoma Refractory
NCT03590574

Recruiting

Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma

Conditions: T Cell Non-Hodgkin Lymphoma; Peripheral T-Cell Lymphoma, Not Otherwise Specified; Angioimmunoblastic T-cell Lymphoma; Anaplastic Large Cell Lymphoma
NCT01198665

Completed

RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas

Conditions: Peripheral T Cell Lymphoma Unspecified; Anaplastic Large Cell Lymphoma, ALK-negative; Angioimmunoblastic T Cell Lymphoma; Cutaneous T Cell Lymphoma
NCT00725231

Unknown status

Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP

Conditions: Peripheral T Cell Lymphoma, Unspecified; Angioimmunoblastic Lymphadenopathy; Extranodal NK/T-cell Lymphoma
NCT01336933

Completed

Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

Conditions: Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Hepatosplenic T-cell Lymphoma; Peripheral T-cell Lymphoma
NCT02223208

Active, not recruiting

Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas

Conditions: Peripheral T-cell Lymphomas (PTCL); PTCL-NOS; Angioimmunoblastic T-cell Lymphoma (AITL); ALK- Anaplastic Large Cell Lymphoma (ALCL); Nodal Peripheral T-Cell Lymphoma of T Follicular Helper Cell Origin
NCT01719835

Active, not recruiting

CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study

Conditions: Peripheral T-cell Lymphoma NOS; Anaplastic Large Cell Lymphoma, ALK-Negative; Angioimmunoblastic T-cell Lymphoma; Hepatosplenic Gamma/ Delta T-cell Lymphoma; Enteropathy-Associated T-Cell Lymphoma
NCT01336920

Completed

Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Peripheral T-cell Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma
NCT02561273

Active, not recruiting

Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma

Conditions: Anaplastic Large Cell Lymphoma, ALK-Negative; Anaplastic Large Cell Lymphoma, ALK-Positive; Hepatosplenic T-Cell Lymphoma; Peripheral T-Cell Lymphoma, Not Otherwise Specified; Stage II Angioimmunoblastic T-cell Lymphoma; Stage II Enteropathy-Associated T-Cell Lymphoma; Stage III Angioimmunoblastic T-cell Lymphoma; Stage III Enteropathy-Associated T-Cell Lymphoma; Stage IV Angioimmunoblastic T-cell Lymphoma; Stage IV Enteropathy-Associated T-Cell Lymphoma
NCT04795869

Not yet recruiting

Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

Conditions: Recurrent Angioimmunoblastic T-Cell Lymphoma; Recurrent Enteropathy-Associated T-Cell Lymphoma; Recurrent Follicular T-Cell Lymphoma; Recurrent Hepatosplenic T-Cell Lymphoma; Recurrent Nodal Peripheral T-Cell Lymphoma With TFH Phenotype; Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified; Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma; Refractory Angioimmunoblastic T-Cell Lymphoma; Refractory Enteropathy-Associated T-Cell Lymphoma; Refractory Follicular T-Cell Lymphoma; Refractory Hepatosplenic T-Cell Lymphoma; Refractory Nodal Peripheral T-Cell Lymphoma With TFH Phenotype; Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified; Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma
NCT03598998

Recruiting

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

Conditions: Anaplastic Large Cell Lymphoma; Nodal Peripheral T-Cell Lymphoma With TFH Phenotype; Recurrent Anaplastic Large Cell Lymphoma; Recurrent Angioimmunoblastic T-Cell Lymphoma; Recurrent Enteropathy-Associated T-Cell Lymphoma; Recurrent Follicular Lymphoma; Recurrent Hepatosplenic T-Cell Lymphoma; Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma; Recurrent Mycosis Fungoides; Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified; Refractory Anaplastic Large Cell Lymphoma; Refractory Angioimmunoblastic T-Cell Lymphoma; Refractory Enteropathy-Associated T-Cell Lymphoma; Refractory Follicular Lymphoma; Refractory Hepatosplenic T-Cell Lymphoma; Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Refractory Mycosis Fungoides; Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified; Subcutaneous Panniculitis-Like T-Cell Lymphoma